Elecsys免疫分析平台血清可溶性fms样酪氨酸激酶1与胎盘生长因子比值预测住院妊娠期高血压疾病孕妇重度子痫前期
本研究基于美国18家医院的前瞻性队列,验证Elecsys平台可溶性fms样酪氨酸激酶1与胎盘生长因子比值>38对住院妊娠期高血压疾病孕妇2周内进展为重度子痫前期的预测价值,结果显示阳性预测值67%、阴性预测值95%,且优于常规临床指标。
要点
- 比值>38预测2周内重度子痫前期阳性预测值67%、阴性预测值95%。
- 孕<30周者比值>38阳性预测值78%、阴性预测值100%。
- 比值>38者不良 maternal 结局风险为比值≤38者的4.9倍。
核心结论
- 在因妊娠期高血压疾病住院的早产孕妇中,Elecsys平台测定的可溶性fms样酪氨酸激酶1与胎盘生长因子比值>38可预测检测后2周内重度子痫前期、分娩及不良母胎/新生儿结局。
研究设计与样本
- 基于Preeclampsia Risk Assessment: Evaluation of Cut-offs to Improve Stratification前瞻性队列的验证研究,纳入美国18家三级和社区医院住院的妊娠期高血压疾病孕妇,孕周23 0/7至34 6/7周,共556例入组。
主要发现
- 比值>38预测2周内重度子痫前期的阳性预测值为67%(95%CI 61-73),阴性预测值为95%(95%CI 92-97)。
- 孕<30周亚组(n=188)比值>38的阳性预测值为78%(95%CI 68-86),阴性预测值为100%(95%CI 96-100)。
- 比值>38者发生不良 maternal 结局的风险为比值≤38者的4.9倍(RR 4.9,95%CI 2.6-9.9;P<.001),发生不良胎儿/新生儿结局的风险为3.2倍(RR 3.2,95%CI 2.6-4.0;P<.001)。
- 比值>38者2周内分娩的可能性更高(校正HR 3.3,95%CI 2.7-4.0;P<.001)。
- 比值预测的ROC曲线下面积为0.92(95%CI 0.89-0.90),优于肝脏酶学、血小板计数和血清肌酐等常规检测(后者ROC曲线下面积<0.70,P<.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previous single-center studies conducted in the United States in women with suspected preeclampsia indicated that serum soluble fms-like tyrosine kinase 1-to-placental growth factor ratio values of >38 measured on a widely available Elecsys immunoassay platform during the third trimester of pregnancy predicted the development of preeclampsia with severe features and adverse outcomes within 2 weeks of testing. OBJECTIVE: This study aimed to validate the Elecsys soluble fms-like tyrosine kinase 1-to-placental growth factor ratio test for the prediction of preeclampsia with severe features in a United States population using the prospective Preeclampsia Risk Assessment: Evaluation of Cut-offs to Improve Stratification cohort that recruited women with a hypertensive disorder of pregnancy (gestational hypertension, chronic hypertension, de novo and superimposed preeclampsia) across 18 tertiary and community hospitals throughout the United States. STUDY DESIGN: We measured soluble fms-like tyrosine kinase 1-to-placental growth factor ratios using the Elecsys platform in archived serum samples from the Preeclampsia Risk Assessment: Evaluation of Cut-offs to Improve Stratification study that recruited hospitalized women with a hypertensive disorder of pregnancy between 23 0/7 and 34 6/7 weeks of gestation. The primary study outcome was prediction of preeclampsia with severe features within 2 weeks after testing. The secondary outcomes included a composite of adverse maternal and fetal/neonatal outcomes and prediction of delivery within 2 weeks. RESULTS: In the validation cohort of the Preeclampsia Risk Assessment: Evaluation of Cut-offs to Improve Stratification study (556 enrollments), the serum soluble fms-like tyrosine kinase 1-to-placental growth factor ratio at a cutoff value of >38 demonstrated a 67% positive predictive value (95% confidence interval, 61-73) and a 95% negative predictive value (95% confidence interval, 92-97) for the progression to preeclampsia with severe features within 2 weeks. Among women at <30 weeks of gestation (n=188), serum soluble fms-like tyrosine kinase 1-to-placental growth factor ratio at a cutoff value of >38 demonstrated a 78% positive predictive value (95% confidence interval, 68-86) and a 100% negative predictive value (95% confidence interval, 96-100) for the progression to preeclampsia with severe features within 2 weeks. The Elecsys soluble fms-like tyrosine kinase 1-to-placental growth factor ratio test performed better than standard-of-care clinical measures, with an area under the receiver operating characteristic curve of 0.92 (95% confidence interval, 0.89-0.90) for soluble fms-like tyrosine kinase 1-to-placental growth factor ratio vs <0.70 for standard-of-care tests, such as liver enzymes, platelet count, and serum creatinine (P<.001). Compared with women with a ratio of ≤38, those with a ratio of >38 had a higher risk of developing adverse maternal (relative risk, 4.9 [95% confidence interval, 2.6-9.9]; P<.001) and fetal/neonatal (relative risk, 3.2 [95% confidence interval, 2.6-4.0]; P<.001) outcomes and were more likely to deliver within 2 weeks (adjusted hazard ratio, 3.3 [95% confidence interval, 2.7-4.0]; P<.001). CONCLUSION: The soluble fms-like tyrosine kinase 1-to-placental growth factor ratio of >38 measured on the Elecsys platform predicted the development of preeclampsia with severe features, delivery, and adverse maternal and fetal/neonatal outcomes within 2 weeks of testing among preterm pregnant women hospitalized with a hypertensive disorder of pregnancy.
引用
- Berg AH, Calsavara VF, Hund M, et al. Serum soluble-fms-like tyrosine kinase 1-to-placental growth factor ratio on Elecsys immunoassay platform predicts preeclampsia with severe features in hospitalized women with hypertensive disorders of pregnancy. Am J Obstet Gynecol. 2025. PMID: 41232788. doi:10.1016/j.ajog.2025.11.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。